Alicia Dafferner

Ms. Alicia Dafferner

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
IAIman Ahmad
Iman Ahmad
ADAlicia Dafferner
Alicia Dafferner
KOKelly A. O’connell
Kelly A. O’connell
KMKamiya Mehla
Kamiya Mehla
BBBradley E. Britigan
Bradley E. Britigan
Maher AbdallaMaher Abdalla
Maher Abdalla
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Tumor hypoxia plays an active role in promoting tumor progression, malignancy, and resistance to therapy in PDAC. We present evidence that nab-paclitaxel–gemcitabine (NPG) and/or a hypoxic tumor microenvironment (TME) up-regulate heme oxygenase-1 (HO-1), providing a survival advantage for tumors. Using PDAC cells in vitro and a PDAC mouse model, we found that NPG chemotherapy up-regulated expression of HO-1 in PDAC cells and increased its nuclear translocation. Inhibition of HO-1 with ZnPP and SnPP sensitized PDAC cells to NPG-induced cytotoxicity (p < 0.05) and increased apoptosis (p < 0.05). Additionally, HO-1 expression was increased in gemcitabine-resistant PDAC cells (p < 0.05), and HO-1 inhibition increased GEM-resistant PDAC sensitivity to NPG (p < 0.05). NPG combined with HO-1 inhibitor inhibited tumor size in an orthotopic model. In parallel, HO-1 inhibition abrogated the influx of macrophages and FoxP3+ cells, while increasing the proportion of CD8+ infiltration in the pancreatic tumors. These effects were mediated primarily by reducing expression of the immunosuppressive cytokine IL-10.

8 February 2017 in Chemico-Biological Interactions
Verified
Journal Article
Open access
PDF file
ADAlicia Dafferner
Alicia Dafferner
SLSofya Lushchekina
Sofya Lushchekina
PMPatrick Masson
Patrick Masson
GXGaoping Xiao
Gaoping Xiao
LSLawrence M Schopfer
Lawrence M Schopfer
Oksana LockridgeOksana Lockridge
Oksana Lockridge
Human butyrylcholinesterase (HuBChE) protects from nerve agent toxicity. Our goal was to determine whether bovine serum could be used as a source of BChE. Bovine BChE (BoBChE) was immunopurified from 100 mL fetal bovine serum (FBS) or 380 mL adult bovine serum by binding to immobilized monoclonal mAb2. Bound proteins were digested with trypsin and analyzed by liquid chromatography-tandem mass spectrometry. The results proved that FBS and adult bovine serum contain BoBChE. The concentration of BoBChE was estimated to be 0.04 μg/mL in FBS, and 0.03 μg/mL in adult bovine serum, values lower than the 4 μg/mL BChE in human serum. Nondenaturing gel electrophoresis showed that monoclonal mAb2 bound BoBChE but not bovine acetylcholinesterase (BoAChE) and confirmed that FBS contains BoBChE and BoAChE. Recombinant bovine BChE (rBoBChE) expressed in serum-free culture medium spontaneously reactivated from inhibition by chlorpyrifos oxon at a rate of 0.0023 min−1 (t1/2 = 301 min−1) and aged at a rate of 0.0138 min−1 (t1/2 = 50 min−1). Both BoBChE and HuBChE have 574 amino acids per subunit and 90% sequence identity. However, the apparent size of serum BoBChE and rBoBChE tetramers was much greater than the 340,000 Da of HuBChE tetramers. Whereas HuBChE tetramers include short polyproline rich peptides derived from lamellipodin, no polyproline peptides have been identified in BoBChE. We hypothesize that BoBChE tetramers use a large polyproline-rich protein to organize subunits into a tetramer and that the low concentration of BoBChE in serum is explained by limited quantities of an unidentified polyproline-rich protein.

20 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
IAIman Ahmad
Iman Ahmad
ADAlicia Dafferner
Alicia Dafferner
RSRamia J. Salloom
Ramia J. Salloom
Maher AbdallaMaher Abdalla
Maher Abdalla
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form, accounting for more than 90% of all pancreatic malignancies. In a previous study, we found that hypoxia and chemotherapy induced expression of Heme Oxygenase-1 (HO-1) in PDAC cells and tissues. Arsenic trioxide (ATO) is the first-line chemotherapeutic drug for acute promyelocytic leukemia (APL). ATO increases the generation of reactive oxidative species (ROS) and induces apoptosis in treated cells. The clinical use of ATO for solid tumors is limited due to severe systemic toxicity. In order to reduce cytotoxic side effects and resistance and improve efficacy, it has become increasingly common to use combination therapies to treat cancers. In this study, we used ATO-sensitive and less sensitive PDAC cell lines to test the effect of combining HO-1 inhibitors (SnPP and ZnPP) with ATO on HO-1 expression, cell survival, and other parameters. Our results show that ATO significantly induced the expression of HO-1 in different PDAC cells through the p38 MAPK signaling pathway. ROS production was confirmed using the oxygen-sensitive probes DCFH and DHE, N-acetyl cysteine (NAC), an ROS scavenger, and oxidized glutathione levels (GSSG). Both ATO and HO-1 inhibitors reduced PDAC cell survival. In combined treatment, inhibiting HO-1 significantly increased ATO cytotoxicity, disrupted the GSH cycle, and induced apoptosis as measured using flow cytometry. ATO and HO-1 inhibition modulated autophagy as shown by increased expression of autophagy markers ATG5, p62, and LC3B in PDAC cells. This increase was attenuated by NAC treatment, indicating that autophagy modulation was through an ROS-dependent mechanism. In conclusion, our work explored new strategies that could lead to the development of less toxic and more effective therapies against PDAC by combining increased cellular stress and targeting autophagy.

14 November 2017 in Chemical Research in Toxicology
Verified
Journal Article
Open access
SOSeda Onder
Seda Onder
ADAlicia Dafferner
Alicia Dafferner
LSLawrence M Schopfer
Lawrence M Schopfer
GXGaoping Xiao
Gaoping Xiao
UYUdaya Yerramalla
Udaya Yerramalla
Oksana LockridgeOksana Lockridge
Oksana Lockridge
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are irreversibly inhibited by organophosphorus pesticides through formation of a covalent bond with the active site serine. Proteins that have no active site serine, for example albumin, are covalently modified on tyrosine and lysine. Chronic illness from pesticide exposure is not explained by inhibition of AChE and BChE. Our goal was to produce a monoclonal antibody that recognizes proteins diethoxyphosphorylated on tyrosine. Diethoxyphosphate-tyrosine adducts for 13 peptides were synthesized. The diethoxyphosphorylated (OP) peptides cross-linked to four different carrier proteins were used to immunize, boost, and screen mice. Monoclonal antibodies were produced with hybridoma technology. Monoclonal antibody depY was purified and characterized by ELISA, western blotting, Biacore, and Octet technology to determine binding affinity and binding specificity. DepY recognized diethoxyphosphotyrosine independent of the amino acid sequence around the modified tyrosine and independent of the identity of the carrier protein or peptide. It had an IC50 of 3 × 10–9 M in a competition assay with OP tubulin. Kd values measured by Biacore and OctetRED96 were 10–8 M for OP-peptides and 1 × 10–12 M for OP-proteins. The limit of detection measured on western blots hybridized with 0.14 μg/mL of depY was 0.025 μg of human albumin conjugated to YGGFL-OP. DepY was specific for diethoxyphosphotyrosine (chlorpyrifos oxon adduct) as it failed to recognize diethoxyphospholysine, phosphoserine, phosphotyrosine, phosphothreonine, dimethoxyphosphotyrosine (dichlorvos adduct), dimethoxyphosphoserine, monomethoxyphosphotyrosine (aged dichlorvos adduct), and cresylphosphoserine. In conclusion, a monoclonal antibody that specifically recognizes diethoxyphosphotyrosine adducts has been developed. The depY monoclonal antibody could be useful for identifying new biomarkers of OP exposure.

15 April 2011 in Cancer Research
Verified
Journal Article
Closed access
SPSamuel J. Pirruccello
Samuel J. Pirruccello
HSHolly Samson
Holly Samson
ADAlicia Dafferner
Alicia Dafferner
SMSarah Maas
Sarah Maas
HJHoward Julius
Howard Julius
JTJames E. Talmadge
James E. Talmadge
Adaptive immunotherapy can augment host immunity, although the outcomes to date in cancer patients have been limited, due in part, to increased numbers of myeloid derived suppressor cells (MDSCs) in the peripheral blood. MDSCs are key cellular regulators that can limit T-cell and dendritic cell (DC) number and function. They are believed to be myeloid precursors that are increased as part of the hematopoietic response to myelosuppression, stress, chemotherapy, and tumor growth. Recently, we found that mononuclear cell apheresis of some cancer patients (melanoma, leukemia and lymphoma), but not normal donors were enriched for hypodense myeloid cells as confirmed by elutriation and Ficoll-Hypaque gradients. These cells are also found in the peripheral blood, although their frequency is enriched by mononuclear cell apheresis. Despite their low density, cytologically they appear as granulocytes containing < 1% bands or metamyelocytes. Phenotypic analysis by flow cytometry revealed that >98% of the granulocytes (FSxSS), were MDSCs, defined as linage−(CD3, CD19 and CD56)DR−CD14dullCD13dull CD11b+CD33+. Consistent with an immature granulocyte phenotype > 50% of the granulocytes were CD16dull/− as compared to 95% of nucleated cells. It is emphasized that this is not observed in all patients and in our limited experience occurs in 20% or less of patients with advanced disease. Enrichment of hypodense MDSCs by Miltenyi magnetic bead selection of CD11b+ cells following subtractive depletion of DR+ cells provided a 60-85% pure population of MDSCs that can suppress an allogeneic T-cell response and by quantitative TaqMan analysis have significantly increased levels of NOS2, IL10, LTB4R1, MPO, MMP9 and VEGFα. We conclude that the majority of MDSCs in cancer patients are immature granulocytes; rather than myeloid precursors, as evidenced by their CD16dull phenotype, a lack of CD34 expression and segmented granulocyte morphology. Further, the presence of hypodense MDSCs has a significant impact on monocyte enrichment (apheresis, elutriation and Ficoll Hypaque separation) for maturation of monocytes into dendritic cells and use as a vaccine. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 453. doi:10.1158/1538-7445.AM2011-453

30 September 2014
Verified
Conference Paper
Closed access
ADAnand Dusad
Anand Dusad
SKSaraswoti Khadge
Saraswoti Khadge
GTGeoffrey Thiele
Geoffrey Thiele
Michael J DuryeeMichael J Duryee
Michael J Duryee
HBHolly C. Britton
Holly C. Britton
JTJames E. Talmadge
James E. Talmadge
Fatty diets can induce low-grade inflammation that we report is increased by chronic alcohol consumption (CAC). CAC as 16.6% of total calories when administered in combination with the Lieber-DeCarli high-fat diet increases inflammation included hepatic and splenic extramedullary hematopoiesis (EMH) as assessed by flow cytometry, immunohistochemistry and a colony forming unit-granulocyte macrophage (CFU-GM) assay. Further, an increased number of hepatic myeloid derived suppressor cells (MDSCs) CD11b+Gr1+ cells that were predominantly Ly6cbr are observed. The increase in MDSCs is associated with an increased number of hepatic non-parenchymal cells including adipocytes (Oil Red O). Consistent with the increased number of hepatic MDSCs and EMH is a decrease in bone marrow cellularity and progenitor cells measured by flow cytometry (Lin-CD11b-Gr1-Sca-1+) and CFU-GM/femur. Unexpectedly, we observed demineralization and osteolytic lesions by micro computed tomography (micro CT) in all bones examined including femur, tibia, fibula and vertebral column that was associated with osteoclast activity (Trap+). Osteolysis was most notable in the fibula and vertebral spurs associated with osteoclast channels, and the demineralization appeared to be associated with areas of active myelopoiesis. The low grade, chronic inflammation associated with the Lieber-DeCarli fatty diet and CAC accelerated the induction of orthotopic 4T1 mammary tumors, resulting in extensive bone osteolysis, demineralization and increased metastases at aberrant sites including splenic, cardiac, hepatic, and extensive lymph node foci in addition to peritoneal and pleural effusions. The latter were haemorrhagic with a predominant nucleated cell infiltrate composed of bands, segs and myelocytes, supporting EMH. These results support the suggestion that a high-fat diet and CAC together increase tumor induction, metastasis and pathology in association with MDSC mobilization, expansion and EMH resulting in increased numbers of osteoclasts, associated bone demineralization and suppression of T-cell frequency and function. These results support the development of combination therapy strategies incorporating multiple molecular therapeutics that inhibit OCs, MDSCs and their associated mediators.